Karyopharm Therapeutics Inc. Email Format

Pharmaceutical ManufacturingMassachusetts, United States201-500 Employees

Karyopharm Therapeutics Inc. is a pharmaceutical manufacturing company headquartered in Newton Center, Massachusetts, focused on developing cancer therapies. Its lead therapy, XPOVIO (selinexor), is a first-in-class inhibitor of exportin 1 (XPO1) and is marketed in the United States for adults with relapsed or refractory multiple myeloma, with approvals in more than 50 ex-U.S. countries. The company is advancing XPO1 biology across hematologic and solid tumors, including myelofibrosis and TP53 wild-type endometrial cancer, and is exploring next-generation compounds such as eltanexor. Karyopharm has an established commercial infrastructure to bring its cancer therapies to patients and employs between 201 and 500 people. Reported revenue is in the range of $100 million to $250 million.

Sign up for free to view info

Company overview Employee directory